Temozolomide Accord

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
27-06-2023
Ciri produk Ciri produk (SPC)
27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
01-07-2015

Bahan aktif:

temozolomide

Boleh didapati daripada:

Accord Healthcare S.L.U.

Kod ATC:

L01AX03

INN (Nama Antarabangsa):

temozolomide

Kumpulan terapeutik:

Antineoplastic agents

Kawasan terapeutik:

Glioma; Glioblastoma

Tanda-tanda terapeutik:

For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

Ringkasan produk:

Revision: 23

Status kebenaran:

Authorised

Tarikh kebenaran:

2010-03-15

Risalah maklumat

                                61
B. PACKAGE LEAFLET
62
PACKAGE LEAFLET: INFORMATION FOR THE USER
TEMOZOLOMIDE ACCORD 5 MG HARD CAPSULES
TEMOZOLOMIDE ACCORD 20 MG HARD CAPSULES
TEMOZOLOMIDE ACCORD 100 MG HARD CAPSULES
TEMOZOLOMIDE ACCORD 140 MG HARD CAPSULES
TEMOZOLOMIDE ACCORD 180 MG HARD CAPSULES
TEMOZOLOMIDE ACCORD 250 MG HARD CAPSULES
temozolomide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Temozolomide Accord is and what it is used for
2.
What you need to know before you take Temozolomide Accord
3.
How to take Temozolomide Accord
4.
Possible side effects
5.
How to store Temozolomide Accord
6.
Contents of the pack and other information
1.
WHAT TEMOZOLOMIDE ACCORD IS AND WHAT IT IS USED FOR
Temozolomide is an antitumour-r medicine.
Temozolomide Accord capsules is used for the treatment of specific
forms of brain tumours:
-
In adults with newly-diagnosedglioblastoma multiforme. Temozolomide is
first used together
with radiotherapy (concomitant phase of treatment) and after that
alone (monotherapy phase of
treatment).
-
In children 3 years and older and adult patients with malignant
glioma, glioblastoma multiforme
or anaplastic Astrocytoma. Tamozolomide is used in these tumours if
they return or get worse
after standard treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE TEMOZOLOMIDE ACCORD
DO NOT TAKE TEMOZOLOMIDE ACCORD
-
if you are allergic to temozolomide or any of the other ingredients of
this medicine (listed in
section 6).
-
if you have had an allergic reaction to another anti-cancer medicine
called 
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Temozolomide Accord 5 mg hard capsules.
Temozolomide Accord 20 mg hard capsules.
Temozolomide Accord 100 mg hard capsules.
Temozolomide Accord 140 mg hard capsules.
Temozolomide Accord 180 mg hard capsules.
Temozolomide Accord 250 mg hard capsules.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
5mg hard capsules
Each hard capsule contains 5 mg temozolomide.
Excipient with known effect:
Each hard capsule contains 168 mg of anhydrous lactose.
20mg hard capsules
Each hard capsule contains 20 mg temozolomide.
Excipients with known effect:
Each hard capsule contains 14.6 mg of anhydrous lactose.
100mg hard capsules
Each hard capsule contains 100 mg temozolomide.
Excipients with known effect:
Each hard capsule contains 73 mg of anhydrous lactose.
140mg hard capsules
Each hard capsule contains 140 mg temozolomide.
Excipients with known effect:
Each hard capsule contains 102.2 mg of anhydrous lactose.
180mg hard capsules
Each hard capsule contains 180 mg temozolomide.
Excipients with known effect:
Each hardcapsule contains 131.4 mg of anhydrous lactose.
250mg hard capsules
Each hard capsule contains 250 mg temozolomide.
Excipients with known effect:
Each hard capsule contains 182.5 mg of anhydrous lactose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
5mg hard capsule.
3
The hard capsules are green/white hard gelatin capsules imprinted
‘TMZ’ on cap & ‘5’ on body.Each
capsule is approximately 15 mm in length.
20 mg hard capsule.
The hard capsules are yellow/ white hard gelatin capsules, imprinted
‘TMZ’ on cap & ‘20’ on body.
Each capsule is approximately 11 mm in length.
100mg hard capsule.
The hard capsules are pink/white hard gelatin capsules, imprinted
‘TMZ’ on cap & ‘100’ on body.
Each capsule is approximately 15 mm in length.
140mg hard capsule.
The hard capsules are transparent blue/white hard gelatin capsules,
imprinted ‘TMZ’ on cap & ‘140’ on
body.
Each capsule is approximately 19
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 27-06-2023
Ciri produk Ciri produk Bulgaria 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 01-07-2015
Risalah maklumat Risalah maklumat Sepanyol 27-06-2023
Ciri produk Ciri produk Sepanyol 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 01-07-2015
Risalah maklumat Risalah maklumat Czech 27-06-2023
Ciri produk Ciri produk Czech 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Czech 01-07-2015
Risalah maklumat Risalah maklumat Denmark 27-06-2023
Ciri produk Ciri produk Denmark 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 01-07-2015
Risalah maklumat Risalah maklumat Jerman 27-06-2023
Ciri produk Ciri produk Jerman 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 01-07-2015
Risalah maklumat Risalah maklumat Estonia 27-06-2023
Ciri produk Ciri produk Estonia 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 01-07-2015
Risalah maklumat Risalah maklumat Greek 27-06-2023
Ciri produk Ciri produk Greek 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Greek 01-07-2015
Risalah maklumat Risalah maklumat Perancis 27-06-2023
Ciri produk Ciri produk Perancis 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 01-07-2015
Risalah maklumat Risalah maklumat Itali 27-06-2023
Ciri produk Ciri produk Itali 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Itali 01-07-2015
Risalah maklumat Risalah maklumat Latvia 27-06-2023
Ciri produk Ciri produk Latvia 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 01-07-2015
Risalah maklumat Risalah maklumat Lithuania 27-06-2023
Ciri produk Ciri produk Lithuania 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 01-07-2015
Risalah maklumat Risalah maklumat Hungary 27-06-2023
Ciri produk Ciri produk Hungary 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 01-07-2015
Risalah maklumat Risalah maklumat Malta 27-06-2023
Ciri produk Ciri produk Malta 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Malta 01-07-2015
Risalah maklumat Risalah maklumat Belanda 27-06-2023
Ciri produk Ciri produk Belanda 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 01-07-2015
Risalah maklumat Risalah maklumat Poland 27-06-2023
Ciri produk Ciri produk Poland 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Poland 01-07-2015
Risalah maklumat Risalah maklumat Portugis 27-06-2023
Ciri produk Ciri produk Portugis 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 01-07-2015
Risalah maklumat Risalah maklumat Romania 27-06-2023
Ciri produk Ciri produk Romania 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Romania 01-07-2015
Risalah maklumat Risalah maklumat Slovak 27-06-2023
Ciri produk Ciri produk Slovak 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 01-07-2015
Risalah maklumat Risalah maklumat Slovenia 27-06-2023
Ciri produk Ciri produk Slovenia 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 01-07-2015
Risalah maklumat Risalah maklumat Finland 27-06-2023
Ciri produk Ciri produk Finland 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Finland 01-07-2015
Risalah maklumat Risalah maklumat Sweden 27-06-2023
Ciri produk Ciri produk Sweden 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 01-07-2015
Risalah maklumat Risalah maklumat Norway 27-06-2023
Ciri produk Ciri produk Norway 27-06-2023
Risalah maklumat Risalah maklumat Iceland 27-06-2023
Ciri produk Ciri produk Iceland 27-06-2023
Risalah maklumat Risalah maklumat Croat 27-06-2023
Ciri produk Ciri produk Croat 27-06-2023
Laporan Penilaian Awam Laporan Penilaian Awam Croat 01-07-2015

Cari amaran yang berkaitan dengan produk ini